相关实验视频

Updated: May 25, 2025

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

对贝克沙罗在预防胆固醇形成中的作用有新的见解:机制和影响

Thamer Abdulla Mohammed¹, Munaf H Zalzala²

¹Ministry of Health and Environment, A State Company That Markets Drugs and Medical Appliances, Baghdad, Iraq. thamer_abdulla@yahoo.com.

Naunyn-Schmiedeberg's archives of pharmacology

|February 26, 2025

概括

贝克萨罗 (Bex) 显示出显著的肝脏保护作用对胆固醇,改善肝功能和减少炎症和氧化应激. 这表明Bex作为胆固醇性肝损伤的潜在治疗剂.

科学领域:

肝病学肝病学是一种肝病学.
药理学药理学是指药理学的学科.
生物化学生物化学

背景情况:

胆固醇症的特点是胆汁流量受损,除了ursodeoxycholic acid (UDCA) 之外,缺乏有效的治疗方法.
法尔内索伊德X受体 (FXR) 在维持胆酸 (BA) 恒温中起着至关重要的作用.
需要新的治疗策略来解决胆固醇性肝脏疾病.

研究的目的:

评估贝克萨罗 (Bex) 对大鼠α-纳非利索酸盐 (ANIT) 诱导的胆固醇衰竭的肝保护作用.
研究贝克斯保护作用背后的分子机制,重点关注FXR信号传递,炎症和氧化应激.

主要方法:

雄性Wistar白色老鼠被给予ANIT以诱导胆.
贝克斯治疗是为了评估其对肝功能测试和组织学的影响.
分析了参与胆酸代谢,炎症和氧化应激的关键分子的基因和蛋白质表达水平.

主要成果:

与仅服用ANIT的组相比,Bex显著改善了肝功能测试和肝脏组织学.
贝克斯治疗显著降低了炎症调解剂,并增加了抗氧化剂水平.
贝克斯对FXR,胆盐出口 (BSEP) 和Nrf2,NQO1和HO-1等抗氧化因子的表达进行了上调.

结论:

贝克斯在老鼠中表现出显著的肝保护潜力,防止ANIT诱导的胆固醇病.
保护机制包括调节胆酸代谢,减轻炎症和减少氧化应激.
贝克斯调节FXR信号传递和增强抗氧化防御的能力支持其对胆固醇性肝脏疾病的治疗承诺.

关键词:

亚尼特 (ANIT) 公司贝克萨罗烯 (bexarotene) 是一种素.胆固醇的形成胆固醇的形成保护作用保护作用保护作用这是一个RXRR.

更多相关视频

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport

Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport

Published on: November 27, 2016

相关概念视频

Hepatic Drug Excretion: Enterohepatic Cycling

Hepatic Drug Excretion: Enterohepatic Cycling

Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...

Hepatic Drug Excretion: Influencing Factors

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...

Hepatic Drug Clearance: Role of Transporters

Hepatic Drug Clearance: Role of Transporters

In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...